US OptionsDetailed Quotes

THTX241220C2500

Watchlist
  • 0.10
  • 0.000.00%
15min DelayClose Nov 26 16:00 ET
0.00High0.00Low
Intraday
  • 5D
  • Daily

News

Comments

    Jaguar8
    Jaguar8
    Oct 17 14:54
    NEWS
    $Theratechnologies (THTX.US)$
    Theratechnologies IDWeek Presentations Highlight the Impact of Excess Visceral Abdominal Fat (EVAF) on Cardiovascular Disease (CVD) Risk in People with HIV
    Theratechnologies Inc. (TSX: TH) (NASDAQ: THTX) presented data at IDWeek 2024 highlighting the impact of excess visceral abdominal fat (EVAF) on cardiovascular disease (CVD) risk in people with HIV (PWH). Two studies were presented:
    1. The VAMOS study showed that EVAF is prevalent (58%) in PWH on modern anti-r...
    Jaguar8
    Jaguar8
    Oct 10 06:31
    NEWS
    $Theratechnologies (THTX.US)$
    Theratechnologies Reports Strong Financial Results and Announces Positive Net Income for Third Quarter 2024
    • Q3 revenue of $22.6 million represents +8% growth year-over-year
    • Positive net income of $3.1 million or 6 cents per share, and Adjusted EBITDA1 of $7.2 million
    • Fiscal 2024 guidance revised to between $83 and $85 million in revenue and Adjusted EBITDA guidance increased to a range of $17 to $19 million
    Jaguar8
    Jaguar8
    May 23 16:02
    $Theratechnologies (THTX.US)$
    NEWS
    Theratechnologies’ Sudocetaxel Zendusortide ASCO 2024 Presentation Demonstrates Signs of Long-Term Efficacy and Manageable Safety Profile in Patients with Solid Tumors
    Theratechnologies announced promising Phase 1 data for its investigational drug, sudocetaxel zendusortide, at the 2024 ASCO annual meeting.
    The drug showed long-term disease stabilization in patients with solid tumors, lasting up to 45 weeks even after treatment ceased.
    The study highlighted a uni...
    Jaguar8
    Jaguar8
    May 2 06:31
    $Theratechnologies (THTX.US)$
    NEWS
    Theratechnologies to Present Long-Term Efficacy, Safety and Pharmacokinetic Data on Use of TH1902 (sudocetaxel zendusortide) in Solid Tumors at 2024 ASCO Meeting
    05/02/2024 - 04:30 AM
    First long-term data presentation from Parts 1 and 2 of the Phase 1 clinical trial of sudocetaxel zendusortide in solid tumors
    Part 3 of Phase 1 trial in advanced ovarian cancer is ongoing
    MONTREAL, May 02, 2024 (GLOBE NEWSWIRE) -- Theratechnologies Inc. (“Theratechnologies” or the...
    Trytosaveabit
    Trytosaveabit
    Mar 21 07:35
    Update
    $Theratechnologies (THTX.US)$ NASDAQ: THTX) announced moving to the next dose level in Part 3 of its Phase 1 clinical trial of sudocetaxel zendusortide in patients with advanced ovarian cancer.
Read more